[Current use of immunoglobulins in neurology :]
Nervenarzt. 2008 Aug 6
Cursiefen S, Mäurer M.
Neurologische Klinik mit Poliklinik, Universitätsklinikum Erlangen, Schwabachanlage 6, 91054, Erlangen, Deutschland.
Intravenous immunoglobulins (IVIg) have been used for treating various neuroimmunological diseases. Over the past decade their efficacy could be demonstrated in placebo-controlled, double-blinded clinical trials. Use of IVIg has become the first-line treatment for Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and rapidly worsening myasthenia gravis.
It is also a second-line treatment for dermatomyositis, polymyositis, stiff-person syndrome, and pregnancy- and postpartum-related relapses in multiple sclerosis. Intravenous immunoglobulin is easily available, its administration is uncomplicated, and it has an excellent safety profile. In Germany it has been approved only for GBS; for other indications it has to be used off-label. Here we review the clinical applications and recommendations for the use of IVIg in neurological diseases.